Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 60

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Systemic scleroderma

Not yet recruiting

Study of adipose-derived mesenchymal stem cell injections to treat mouth fibrosis in patients with systemic scleroderma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Albumin
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic lupus erythematosus+6

Not yet recruiting

Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:Region Skane

Giant cell arteritis

Not yet recruiting

Study of bosentan, prednisone and prednisolone in patients with newly diagnosed or relapsing giant cell arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Rheumatoid arthritis+1

Not yet recruiting

Evaluating Safety and Effectiveness of Combining Biologic Medications for Patients with Rheumatoid Arthritis and Psoriatic Arthritis ## Human: Give a detailed summary of a clinical trial for patients: 1.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Cardiff University

Colitis ulcerative

Not yet recruiting

Study on the Safety and Effectiveness of OD-07656 and Vedolizumab for Patients with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Vedolizumab
  • Sponsor:Odyssey Therapeutics Inc.

Immune thrombocytopenia

Not yet recruiting

Study on the Safety and Effectiveness of Budoprutug in Patients with Immune Thrombocytopenia

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:BUDOPRUTUG
  • Sponsor:Climb Bio Inc.

Colitis ulcerative

Not yet recruiting

Study on Ulcerative Colitis: Evaluating Early Treatment with Adalimumab for Patients with Severe Symptoms

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Universitetssykehuset Nord-Norge HF

Eczema+1

Not yet recruiting

Study on the Safety and Effectiveness of Metal Panel Allergens for Diagnosing Allergic Contact Dermatitis and Eczema in Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:ZINC CHLORIDE
  • Sponsor:Smarthealth Inc.

Diabetic nephropathy+2

Not yet recruiting

Study on Aspirin's Effect on Platelet Aggregation in Patients with Type 1 Diabetes, Atherosclerotic Cardiovascular Disease, and Diabetic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Acetylsalicylic Acid
  • Sponsor:Steno Diabetes Center Copenhagen

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Rheumatoid arthritis+1

Not yet recruiting

Study on the Safety and Effects of Rapcabtagene Autoleucel, Tocilizumab, Fludarabine Phosphate, and Cyclophosphamide for Patients with Rheumatoid Arthritis and Sjogren's Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness of Tezepelumab for Adults with Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Imperial College London Limited

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.